Stock IPH INNATE PHARMA
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Innate Pharma

Equities

IPH

FR0010331421

Market Closed - Euronext Paris
Other stock markets
 16:35:16 30/04/2024 BST 		5-day change 1st Jan Change
2.205 EUR -1.12% Intraday chart for Innate Pharma +1.85% -15.84%
04-15 Sanofi: progress in hematology trial CF
04-15 Innate Pharma: progress in hematology trial CF

Evolution of the average Target Price on Innate Pharma

Price target over the last 5 years

History of analyst recommendation changes

c9633f72af7d3ac751.0a0Fupp5kDoOP6TD1JDZ0a7uvuk3VKyyWhyKO4c4Oac.mf1Sw_UO4FM2TumypKWVkJ6_56dPMMrmbS_rA_Z6DOiw1XzcrzLeVVR19Q~b51689a39322816a7c3b6e661838a0cf

Analyst Recommendations on Innate Pharma

ANALYST RECOMMENDATIONS : BHP, Lear, Naked Wines, Teradata, Visteon... Our Logo
Innate Pharma S A : Shares Jump After SVB Leerink Upgrades Rating to Outperform MT
INNATE PHARMA S A : SVB Leerink Upgrades Innate Pharma to Outperform from Market Perform MT
INNATE PHARMA S A : SVB Leerink Downgrades Innate Pharma to Market Perform From Outperform, Adjusts Price Target to $5 From $7 MT
INNATE PHARMA S A : HC Wainwright Adjusts Innate Pharma's Price Target to $11.50 From $13, Keeps at Buy MT
INNATE PHARMA S A : Goldman Sachs Starts Innate Pharma at Neutral With $4.75 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.205 EUR
Average target price
6.27 EUR
Spread / Average Target
+184.35%
High Price Target
8.4 EUR
Spread / Highest target
+280.95%
Low Price Target
2.25 EUR
Spread / Lowest Target
+2.04%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Innate Pharma

SVB Leerink

Ratings for Innate Pharma

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. IPH Stock
  4. Consensus Innate Pharma